Skip to content
PoliticalRepoPoliticalRepo

Person

Official portrait of Rep. Grijalva, Adelita S. [D-AZ-7]

Rep. Grijalva, Adelita S. [D-AZ-7]

United States · Official source

Records

453 records where Rep. Grijalva, Adelita S. [D-AZ-7] is listed as a sponsor, author, or other actor. Search with topics and years

Bill· HRH.R. 8788 (119th)referred

Let Kids Play Act

United States · United States Congress · 13 May 2026

Bill· HRH.R. 8744 (119th)referred

TREE Act

United States · United States Congress · 12 May 2026

Bill· HRH.R. 8667 (119th)referred

MISSION Rx Act

United States · United States Congress · 7 May 2026

Bill· HRH.R. 8592 (119th)referred

No WAR Act

United States · United States Congress · 30 April 2026

No War Appropriations through Reconciliation Act or the No WAR Act This bill establishes a budget point of order that prohibits considering reconciliation legislation that provides funding for unauthorized military force against Iran. (Reconciliation is an expedited method by which Congress may adopt changes in spending and revenue laws to achieve the budgetary goals reflected in a congressional budget resolution. Reconciliation bills are considered by Congress using expedited legislative procedures that prevent a filibuster and restrict amendments in the Senate.) Specifically, the point of order may be raised to prohibit the consideration of reconciliation legislation that provides budget authority for hostilities, including hostilities conducted by a proxy force, against Iran unless Congress has authorized such hostilities through a declaration of war or a specific authorization for use of military force. Under the bill, hostilities includes any offensive military operation, strike, covert action, or sustained engagement involving armed conflict against Iranian military forces, territory, or government institutions.  The point of order may be waived by a vote of at least three-fifths of all Senators duly chosen and sworn (60 votes if there are no vacancies).

Bill· HRH.R. 8612 (119th)referred

Reward Work Act

United States · United States Congress · 30 April 2026

Bill· HRH.R. 8632 (119th)referred

PFAS Cleanup Act

United States · United States Congress · 30 April 2026

Bill· HRH.R. 8606 (119th)referred

CHARTER Act

United States · United States Congress · 30 April 2026

Bill· HRH.R. 8540 (119th)referred

HCBS Access Act

United States · United States Congress · 28 April 2026

Resolution· HRESH.Res. 1212 (119th)referred

Expressing support for the staff of public, school, academic, and special libraries in the United States and the essential services those libraries provide to communities, recognizing the need for funding commensurate with the broad scope of social service and community supports provided by libraries, preserving the right of all citizens of the United States to freely access information and resources in their communities, supporting a strong union voice for library workers, and defending the civil rights of library staff.

United States · United States Congress · 23 April 2026

Bill· HRH.R. 8475 (119th)referred

Savings Opportunity and Affordable Repayment Act

United States · United States Congress · 23 April 2026

Savings Opportunity and Affordable Repayment Act This bill creates a new income-driven repayment plan for student loans called the Savings Opportunity and Affordable Repayment (SOAR) plan. The SOAR plan has similar provisions to, but further expands on, the Department of Education's (ED's) final rule published on July 10, 2023, that created the Saving on a Valuable Education (SAVE) plan. The SAVE plan was blocked by federal courts. The bill directs ED to carry out a SOAR plan program that complies with specified requirements. The bill allows all federal student loan types to be eligible for repayment under the SOAR plan, including Parent PLUS Loans and Federal Family Education Loans. Under the SOAR plan, a federal student loan borrower whose income is at or below 250% of the federal poverty level (FPL) has $0 monthly payments. A borrower whose income is over 250% of the FPL pays 5% of their discretionary income on loans obtained for undergraduate study and 10% of their discretionary income for all other outstanding loans (e.g., loans obtained for graduate study). Additionally, under the SOAR plan, holders of eligible federal student loans (e.g., ED or private lenders) must apply 50% of the borrower's monthly payment toward outstanding principal. The other 50% must be applied in the following order: (1) accrued charges and collection costs on the loan, (2) outstanding interest, and (3) outstanding principal. ED must forgive any loan balance that remains outstanding after a specified maximum repayment period (e.g., 10 years or 15 years).

Bill· HRH.R. 8205 (119th)open

Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026

United States · United States Congress · 6 April 2026

Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026 This bill reauthorizes through FY2031 and revises programs that support research and development of drugs and other therapies to address amyotrophic lateral sclerosis (also known as ALS or Lou Gehrig's disease) and other neurodegenerative diseases. The bill reauthorizes grants from the National Institutes of Health (NIH) for scientific research on investigational drugs to prevent or treat ALS for individuals not otherwise eligible for clinical trials, grants from the Food and Drug Administration (FDA) for research and development of therapies to prevent and treat ALS and other neurodegenerative diseases, and a Public-Private Partnership including the FDA and NIH that supports development and regulatory review of treatments for neurodegenerative diseases.  Also, the NIH, in considering renewal of its grants, must assess available information on the safety and efficacy of the investigational drugs. It must also require grantees to promptly report serious and unexpected adverse events associated with their investigational drugs. Additionally, the FDA must publish a plan describing actions it will take over a five-year period to foster development of safe and effective drugs, and facilitate access to investigational drugs, that treat ALS and other rare neurodegenerative diseases. The FDA must also publish a report describing the actions it has taken under the plan.